Search
Search
Search results 17
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS® (Sotorasib)
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyD
News & Events
Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership
The 2nd Roche Pan-Tumor Precision Medicine Innovation Forum was officially held at the Shanghai Roche Pharmaceuticals Campus, where participants had discussions on recent progresses in this field.
News & Events
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
News & Events
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection
Recently, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect NTRK1/2/3 gene fusions.
News & Events
Pan Lung Cancer PCR Panel
PRODUCTS
NTRK Gene Fusions Detection Kit
PRODUCTS
HANDLE Classic NGS Panel
PRODUCTS
LCP32-L2-01 ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
DOWNLOAD
NTRK Safety Data Sheet
DOWNLOAD
AmoyDx® NTRK Gene Fusions Detection Kit-B1.1-24T-RUO
DOWNLOAD
no more...
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS® (Sotorasib)
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyD
News & Events
Amoy Diagnostics and Roche Pharma China Jointly Announce Strategic Partnership
The 2nd Roche Pan-Tumor Precision Medicine Innovation Forum was officially held at the Shanghai Roche Pharmaceuticals Campus, where participants had discussions on recent progresses in this field.
News & Events
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
News & Events
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection
Recently, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect NTRK1/2/3 gene fusions.
News & Events
no more...
no more...
Inquiry
* Required information
Manage your account info
Change your password